Deerfield secures more than $600M for its next biotech venture fund
The firm, a prolific backer of drug startups, will use the cash to back companies working on therapeutics, medical devices and healthcare services.


The firm, a prolific backer of drug startups, will use the cash to back companies working on therapeutics, medical devices and healthcare services.